Apricus Expands Exclusive License Agreement With Sandoz Affiliate, Apricus to Receive Up to $63M in Milestone Payments
December 16, 2013 at 07:09 AM EST
Apricus Biosciences (Nasdaq: APRI ) announced today that it has expanded its exclusive license agreement with Hexal AG, an affiliate within the Sandoz Division of the Novartis Group (NYSE: NVS ) of Companies ("Sandoz"), for the commercialization of Vitaros®, indicated for the treatment of patients with erectile dysfunction